NY Times
NOVEMBER 27, 2020
Court filings reveal consultants’ talk of a records purge during the opioid crisis, and shed new light on sales advice given to the billionaire Sackler family and their drug company, Purdue Pharma.
pharmaphorum
NOVEMBER 27, 2020
A new EMA approval has expanded the use of Vertex Pharma’s exon-skipping cystic fibrosis therapy Symkevi to children as young as six if they have specific gene mutations. The regulator has given a green light to use of Symkevi (tezacaftor/ivacaftor) with Vertex’ Kalydeco (ivacaftor) in patients ages six years and older who have two copies of the F508del mutation in the CFTR gene, or one F508del copy and one of 14 other so-called “minimal function” mutations in CFTR.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
NOVEMBER 27, 2020
It is hoped that the test will help detect cancer at a much earlier stage
Drug Patent Watch
NOVEMBER 27, 2020
Annual Drug Patent Expirations for KORLYM Korlym is a drug marketed by Corcept Therap and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph…. The post New patent for Corcept Therap drug KORLYM appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
NY Times
NOVEMBER 21, 2020
The furious race to develop a coronavirus vaccine played out against a presidential election, between a pharmaceutical giant and a biotech upstart, with the stakes as high as they could get.
pharmaphorum
NOVEMBER 27, 2020
Amanda Barrell explores how a perfect storm of changing economics, advances in technology, and the increasing volume of the patient voice is stoking change in the rare disease space. New models of drug development are fuelling life-changing advantages in the rare disease space, previously an economic no-go area for pharma and biotech companies. That was among the discussion points during Fighting Rare Diseases – The Science, Economics and the Patients , a webinar hosted by o2h Group.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Drug Patent Watch
NOVEMBER 25, 2020
Annual Drug Patent Expirations for XYOSTED+%28AUTOINJECTOR%29 Xyosted (autoinjector) is a drug marketed by Antares Pharma Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Antares Pharma drug XYOSTED (AUTOINJECTOR) appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
NOVEMBER 23, 2020
The billionaire is working with the W.H.O., drugmakers and nonprofits to defeat the coronavirus everywhere, including in the world’s poorest nations. Can they do it?
pharmaphorum
NOVEMBER 23, 2020
Janssen’s Daniel de Schryver tells us why it’s time to give patients a permanent seat at the table and improve health outcomes through patient-pharma dialogue. I’m struck by just how much we thrive when we share a common purpose; when – as a society, a group or a family unit – we work together to achieve the same goal. It’s no different in healthcare.
Pharma Times
NOVEMBER 27, 2020
The combination is the first available to treat the underlying cause of CF in this patient group.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Patent Watch
NOVEMBER 24, 2020
Annual Drug Patent Expirations for RISPERDAL+CONSTA Risperdal Consta is a drug marketed by Janssen Pharms and is included in one NDA. It is available from one supplier. There is one…. The post New patent expiration for Janssen Pharms drug RISPERDAL CONSTA appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
NOVEMBER 23, 2020
The drug maker said its vaccine candidate was 70 percent effective on average, and potentially up to 90 percent effective, at preventing Covid-19 in an early analysis.
pharmaphorum
NOVEMBER 24, 2020
A merger involving two US digital health specialists and a blank cheque company has created a telemedicine player, called UpHealth, that is valued at more than $1.3 billion. The three-way deal combines UpHealth – which provides patient care management, telemedicine and digital pharmacy services and gives its name to the new group – with CloudBreak, which provides a video consultation platform for doctors and patients.
Outsourcing Pharma
NOVEMBER 25, 2020
The new EU Pharmaceutical Strategy, adopted today by the European Commission, is designed to improve and accelerate patientsâ access to safe and affordable medicines and address unmet medical needs in the areas of antimicrobial resistance, cancer, and rare diseases.
Drug Patent Watch
NOVEMBER 26, 2020
Annual Drug Patent Expirations for NEUPRO Neupro is a drug marketed by Ucb Inc and is included in one NDA. It is available from one supplier. There are eight patents…. The post New patent expiration for Ucb Inc drug NEUPRO appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
NOVEMBER 25, 2020
New report conducted by Imperial College London researchers and Philips UK highlights issues within the NHS
pharmaphorum
NOVEMBER 25, 2020
An artificial intelligence tool developed by GE Healthcare twinned with a mobile X-ray device can help the placement of endotracheal tubes (ETTs), a necessary step for COVID-19 patients who require ventilation. The new tool – part of GE’s Critical Care Suite 2.0 – helps bedside staff and radiologists assess patients before intubation and make sure ETTs are positioned correctly which should reduce complications.
Outsourcing Pharma
NOVEMBER 23, 2020
The pharma giant and the clinical-stage drug developer will join on a pilot study investigating a candidateâs potential in overcoming resistance of a cancer drug.
NY Times
NOVEMBER 22, 2020
The nonprofit marketing group led a polio vaccine campaign in the 1950s. Now it is working on a $50 million ad blitz to counter concerns about coming treatments.
Pharma Times
NOVEMBER 23, 2020
R&D spending in the sector last year represents an eight-year high
pharmaphorum
NOVEMBER 25, 2020
AstraZeneca’s research chief has said that the more effective dosing regimen of its coronavirus vaccine was discovered by accident. According to Reuters , the AstraZeneca development team made a minor mistake that made them realise they could significantly boost the success rate of the vaccine, codenamed AZD1222. Results announced earlier this week showed that by giving a half dose, followed by a full dose a month later, the vaccine’s efficacy could be boosted from 62% to around 90%.
Outsourcing Pharma
NOVEMBER 24, 2020
The two companies will collaborate on a Phase III clinical trial investigating a potential treatment for patients hospitalized with COVID-19.
NY Times
NOVEMBER 22, 2020
The nonprofit marketing group led a polio vaccine campaign in the 1950s. Now it is working on a $50 million ad blitz to counter concerns about coming treatments.
Pharma Times
NOVEMBER 25, 2020
Deal will focus on developing small molecules against a number of diseases
pharmaphorum
NOVEMBER 25, 2020
Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition in the coming years, analysts have said. Following a briefing with management, a team of analysts led by Peter Welford said that the big Swiss pharma will be propped up by its psoriasis and infectious diseases blockbuster Cosentyx for some time.
Drug Patent Watch
NOVEMBER 27, 2020
Annual Drug Patent Expirations for FORADIL Foradil is a drug marketed by Novartis and is included in two NDAs. There is one patent protecting this drug. This drug has twenty-eight…. The post New patent expiration for Novartis drug FORADIL appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
NOVEMBER 23, 2020
El desarrollo veloz de una vacuna contra la COVID-19 sucedió durante una elección presidencial y entre un gigante farmacéutico y una pequeña empresa recién llegada de la biotecnología. Las apuestas eran muy altas.
Pharma Times
NOVEMBER 24, 2020
MenQuadfi approved for vaccination in individuals 12 months of age or older
pharmaphorum
NOVEMBER 26, 2020
COVID-19 is proving to be the perfect storm in terms of the supply of pharmaceutical products. But learning how to overcome the challenges of 2020 will serve the industry well for years to come. As part of our EU Leader series, Christian Pawlu, head of strategy, portfolio and BD&L at Sandoz, told us about how securing supply in a time of crisis will ensure future access, build resilience, and transform relationships.
Outsourcing Pharma
NOVEMBER 23, 2020
The agency has given the go-ahead for use of baricitinib in conjunction with remdesivir for treating patients hospitalized with severe cases of the virus.
Drug Patent Watch
NOVEMBER 27, 2020
Annual Drug Patent Expirations for MONISTAT+1+COMBINATION+PACK Monistat 1 Combination Pack is a drug marketed by Medtech Products and is included in one NDA. It is available from one supplier. There…. The post New patent expiration for Medtech Products drug MONISTAT 1 COMBINATION PACK appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
NOVEMBER 25, 2020
Shot will be evaluated in pregnant mothers and their newborn infants
pharmaphorum
NOVEMBER 24, 2020
The developer of Russia’s COVID-19 vaccine Sputnik V has pledged to make it available for less than $10 per dose – or $20 per two-dose course – on the same day as revealing new clinical data with the shot. Sputnik V ’s efficacy has remained high at 91.4% according to the latest analysis, which comes from almost 19,000 subjects who were assessed seven days after the second dose of the vaccine, administered 28 days after the first.
Pharma Mirror
NOVEMBER 24, 2020
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NS
Drug Patent Watch
NOVEMBER 27, 2020
Annual Drug Patent Expirations for TAZVERIK Tazverik is a drug marketed by Epizyme Inc and is included in one NDA. There are twenty-one patents protecting this drug. This drug has…. The post New patent for Epizyme Inc drug TAZVERIK appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
145 
Let's personalize your content